Welcome to Awesome Blog Design perfect blog
Business, Healthcare, Local News

European Medicines Agency validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as adjuvant treatment for resected esophageal or gastroesophageal junction cancer following chemoradiotherapy

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #BMS—Bristol Myers Squibb (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for Opdivo (nivolumab) as an adjuvant treatment for esophageal or gastroesophageal junction (GEJ) cancer in adult patients